Year archive

Lytix Biopharma AS — 2021 filings

All 30 regulatory filings released by Lytix Biopharma AS (LYTIX) in 2021, sourced directly from the official regulator.

30 Filings

2021 Period

2021 filings (30)

Filing	Released	Lang
Finansiell kalender Report Publication Announcement	2021-12-17	Norwegian
Financial calendar Report Publication Announcement	2021-12-17	English
Lytix Biopharma AS Announces that First Patient Started Treatment in the ATLAS-IT-05 clinical trial Regulatory Filings	2021-12-08	English
Lytix Biopharma third quarter 2021 results Investor Presentation Q3 2021	2021-11-25	English
Lytix Biopharma third quarter 2021 results Earnings Release Q3 2021	2021-11-25	English
Lytix Biopharma: Invitation to presentation of third quarter 2021 results, Thursday 25 November Report Publication Announcement	2021-11-22	English
Lytix presents encouraging preclinical data in triple negative breast cancer in collaboration with Weill Cornell Medicine Regulatory Filings	2021-11-12	English
Lytix Biopharma granted European Patent for LTX-315 in combination with chemotherapeutic agent Regulatory Filings	2021-10-22	English
Lytix Biopharma AS to Present at Investordagene 2021 Investor Presentation	2021-10-20	English
Lytix Biopharma AS to Present at Investordagene 2021 Report Publication Announcement	2021-10-20	English
Lytix Biopharma strengthens patent protection of lead candidate LTX-315 in the US Regulatory Filings	2021-09-22	English
Lytix Biopharma second quarter and first half of 2021 results: Fueled to target the US cancer market Interim / Quarterly Report H1 2021	2021-08-27	English
Lytix Biopharma second quarter and first half of 2021 results: Fueled to target the US cancer market Investor Presentation	2021-08-27	English
Lytix Biopharma second quarter and first half of 2021 results: Fueled to target the US cancer market Earnings Release H1 2021	2021-08-27	English
Lytix Biopharma: Invitation to presentation of first half and second quarter 2021 results, Friday 27 August Report Publication Announcement	2021-08-20	English
Lytix Biopharma initiates the Phase II combination study in the US with LTX-315 and Pembrolizumab in patients with solid tumors Regulatory Filings	2021-07-15	English
Lytix Biopharma: Company presentation in connection with first day of trading on Euronext Growth Oslo Share Issue/Capital Change	2021-06-14	English
Lytix Biopharma: Company presentation in connection with first day of trading on Euronext Growth Oslo Report Publication Announcement	2021-06-14	English
Lytix Biopharma AS: Publication of Information Document Capital/Financing Update	2021-06-13	English
Lytix Biopharma AS: Publication of Information Document Report Publication Announcement	2021-06-13	English
Lytix Biopharma AS: New share capital registered Share Issue/Capital Change	2021-06-11	English
Euronext Growth - Resolution for admission to trading – Lytix Biopharma AS Delisting Announcement	2021-06-10	English
Lytix Biopharma AS – minutes from the annual general meeting 2021 AGM Information	2021-06-07	Norwegian
Lytix Biopharma AS – minutes from the annual general meeting 2021 AGM Information	2021-06-07	Norwegian
Lytix Biopharma AS: Private placement successfully placed Share Issue/Capital Change	2021-06-07	English
Finansiell kalender Report Publication Announcement	2021-06-06	Norwegian
Lytix Biopharma AS: Status of bookbuilding - Increased size of private placement Share Issue/Capital Change	2021-06-03	English
Euronext Growth - Received application for admission to trading – Lytix Biopharma AS Regulatory Filings	2021-06-01	English
Euronext Growth - Mottatt søknad om opptak til handel – Lytix Biopharma AS Regulatory Filings	2021-06-01	Norwegian
Lytix Biopharma AS: Contemplated private placement and listing on Euronext Growth Oslo Capital/Financing Update	2021-05-31	English